Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518520 | 0.97 | MAPK14 (0.39) | MAPK14MAPK11ACLYMAPKAPK2PTGER1 | |
| SCHEMBL3525407 | 0.93 | MAPK14 (0.42) | MAPK14MAPK11MAPKAPK2PTGER1KDM4E | |
| SCHEMBL3522183 | 0.91 | MAPK14 (0.40) | MAPK14MAPK11ACLYMAPKAPK2KDM4E | |
| SCHEMBL3518626 | 0.91 | MAPK14 (0.43) | MAPK14MAPK11KDM4E | |
| SCHEMBL3520157 | 0.91 | MAPK14 (0.41) | MAPK14MAPK11MAPKAPK2PTGER1KDM4E | |
| SCHEMBL3526558 | 0.90 | MAPK14 (0.42) | MAPK14MAPK11KDM4E | |
| SCHEMBL3522788 | 0.90 | MAPK14 (0.42) | MAPK14MAPK11KDM4E | |
| SCHEMBL3525469 | 0.90 | MAPK14 (0.43) | MAPK14MAPK11PTGER1KDM4E | |
| SCHEMBL3523222 | 0.90 | MAPK14 (0.42) | MAPK14MAPK11KDM4E | |
| SCHEMBL3527512 | 0.89 | MAPK14 (0.42) | MAPK14MAPK11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885MAPK11 43/4885ACLY 2865/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885MAPK11 48/4885ACLY 3293/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885MAPK11 43/4885ACLY 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.